Vertex Pharmaceuticals Incorpor vs Incyte Corporation
A head-to-head of Vertex Pharmaceuticals Incorpor (VRTX) and Incyte Corporation (INCY) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | VRTX | INCY |
|---|---|---|
| Market Cap | $123.26B | $23.42B |
| P/E (TTM) | 28.80 | 16.56 |
| Forward P/E | 20.21 | 10.52 |
| P/S | 9.03 | 3.55 |
| P/B | 6.38 | 4.17 |
| EV/EBITDA | 21.08 | 9.71 |
| Dividend Yield | — | — |
| Profit Margin | 35.51% | 26.71% |
| Gross Margin | 86.24% | 92.76% |
| Operating Margin | 37.95% | 26.12% |
| Revenue Growth (YoY) | +7.82% | +20.87% |
| FCF Yield | 3.36% | 7.47% |
| Debt / Equity | 10.26 | 0.70 |
| Current Ratio | 3.02 | 3.68 |
Which is better: Vertex Pharmaceuticals Incorpor or Incyte Corporation?
- ✓Larger by market cap: Vertex Pharmaceuticals Incorpor
- ✓Cheaper valuation (lower P/E): Incyte Corporation
- ✓More profitable (net margin): Vertex Pharmaceuticals Incorpor
- ✓Faster revenue growth: Incyte Corporation
- ✓Higher free-cash-flow yield: Incyte Corporation
Across 12 available metrics, Incyte Corporation leads 10–2.
There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.
Share:
Compare Vertex Pharmaceuticals Incorpor with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.